Navigation Links
Despite Generic Erosion of Key Brands, the Hospital-Acquired Gram Negative Infections Drug Market Will Increase by $1 Billion from 2008 to 2018
Date:6/16/2009

Uptake of Novel Agents from Novexel, Johnson & Johnson and Wyeth Will Drive Growth, According to a New Report from Decision Resources

WALTHAM, Mass., June 16 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, despite generic erosion of key brands, the hospital-acquired gram-negative infections drug market will increase by $1 billion from 2008 to 2018 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

The new Pharmacor report entitled Gram Negative Infections finds that the introduction and uptake of next-generation cephalosporins, carbapenems, quinolones, and beta-lactam/beta-lactamase inhibitors, will be a significant driver of market growth through 2018. Among these emerging therapies, Novexel's NXL-104/ceftazidime, a novel beta-lactam/beta-lactamase inhibitor agent, is positioned to offer the most significant advance in the treatment of hospital-acquired gram-negative infections and will earn more than $250 million in sales in 2018. Additionally, the continued uptake of two recent market entrants -- Johnson & Johnson's Doribax and, to a lesser extent, Wyeth's Tygacil -- will also drive the market. Although these three agents and several other emerging therapies will drive market growth, generic erosion of key brands will temper overall market sales through 2018, according to the report.

Generic erosion of top branded products such as piperacillin/tazobactam (Wyeth's Zosyn/Tazocin), imipenem/cilastatin (Merck's Primaxin/Tienam), meropenem (Cubist Pharmaceuticals/AstraZeneca's Merrem/Meronem) and levofloxacin (Johnson & Johnson's Levaquin, Sanofi-Aventis's Tavanic and Daiichi Sankyo's Cravit) will have the greatest impact on the market. In 2008, these four products accounted for approximately 50 percent of the hospital-acquired gram-negative infections market. The report forecasts that, in 2018, generic erosion will reduce the combined sales of these agents to approximately 25 percent of the market.

The report also finds that drug development for gram-negative infections has been slow and overshadowed by interest and investment in developing novel therapies for the more lucrative market of hospital-acquired infections due to gram-positive pathogens, namely, methicillin-resistant Staphylococcus aureus (MRSA). However, as competition increases and opportunities decline in the market for hospital-acquired infections due to MRSA, the hospital-acquired gram-negative infections market segment is ripe with attractive drug development opportunities.

"Competition between agents is relatively low in the hospital-acquired gram-negative infections market when compared with the market for hospital-acquired infections due to gram-positive pathogens," said Decision Resources Analyst Hemali Patel, Ph.D. "Minimal competition in the late-stage pipeline and high unmet need will allow novel agents with clearly demonstrated efficacy against key gram-negative pathogens to command a high price and favorable formulary position -- two key attributes that underlie commercial success in this market."

About Decision Resources

Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources, Inc. company.

About Decision Resources, Inc.

Decision Resources, Inc. is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources, Inc. at www.DecisionResourcesInc.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.

    For more information, contact:

    Decision Resources                              Decision Resources, Inc.
    Christopher Comfort                             Elizabeth Marshall
    781-296-2597                                    781-296-2563
    ccomfort@dresources.com                         emarshall@dresources.com


'/>"/>
SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Despite overeating, morbidly obese mice gain protection against diabetes
2. Despite grumbling, most Americans say they are happy at work
3. Most patients who have male-to-female sex-change surgery are happy, despite complications
4. Cataract Surgery: A Bargain, Despite the Price
5. UGA study: Youth exposed to smokeless tobacco ads despite settlement
6. Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities
7. Plastic Surgery Complications and Deaths are Rare, Despite Highly Publicized Death of Donda West
8. A Full and Long Life, Despite Diabetes
9. Enrollment Growth Slows at U.S. Nursing Colleges and Universities in 2007 Despite Calls for More Registered Nurses
10. Research finds allergic children exposed to peanuts at younger ages despite recommendations to avoid
11. Miscarriage myths persist despite prevalence of medical information
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/9/2016)... ... December 09, 2016 , ... "I have gout, and I wanted ... family recipe, which is meant to relieve gout and pain caused by varicose veins. ... energy boost every time. It relieved what VA doctors called the worst sinusitis case ...
(Date:12/9/2016)... ... December 09, 2016 , ... The ... Hotel in New York, NY, on December 3rd, to benefit Holy Name Medical ... the annual event, which raised over $1 million - the largest event in ...
(Date:12/8/2016)... ... December 08, 2016 , ... The Florida Hospital ... and Hyperbaric Medical Society (UHMS), the leading authority in hyperbaric medicine. This accreditation ... a few hospitals and facilities have earned this distinction. This is the second ...
(Date:12/8/2016)... ... December 08, 2016 , ... Mirixa Corporation , ... and other pharmacist-delivered patient care services, has announced the promotions of Karen Litsinger ... vice president of sales. , Litsinger joined Mirixa in 2008 after serving ...
(Date:12/8/2016)... ... December 08, 2016 , ... SunView Software aims to ... that are both engaging and easy to use. Coming off the heels of ... revealed today its plans to roll out new AI-powered self-service enhancements to help ...
Breaking Medicine News(10 mins):
(Date:12/9/2016)... 9, 2016 Research and Markets has ... Forecast to 2021" report to their offering. ... Market growth ... models in the pharmaceutical and biotechnology industry and technological advancements ... funding. Emerging markets and growing research activities in toxicology and ...
(Date:12/9/2016)... -- RxWiki Inc., a digital health company that powers the ... of pharmacies through its Digital Pharmacist SaaS platform, today ... on Fire" Award in the Health and Life Sciences ... award as one of Austin,s fastest growing companies," said ... "Our platform gives independent retail pharmacies the digital tools ...
(Date:12/9/2016)... SAN DIEGO , Dec. 9, 2016 /PRNewswire/ ... with Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ... program targeting ,LpxC, for the treatment of bacterial ... LpxC has been recognized as an attractive antibacterial ... however, a lack of suitable chemical starting points ...
Breaking Medicine Technology: